WO1998048839A1 - Compositions antiinflammatoires pour application nasale topique - Google Patents

Compositions antiinflammatoires pour application nasale topique Download PDF

Info

Publication number
WO1998048839A1
WO1998048839A1 PCT/US1998/006483 US9806483W WO9848839A1 WO 1998048839 A1 WO1998048839 A1 WO 1998048839A1 US 9806483 W US9806483 W US 9806483W WO 9848839 A1 WO9848839 A1 WO 9848839A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
agent
group
nasal
topical
Prior art date
Application number
PCT/US1998/006483
Other languages
English (en)
Inventor
Catherine A. Segal
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to BR9809022-4A priority Critical patent/BR9809022A/pt
Priority to CA002281789A priority patent/CA2281789A1/fr
Priority to AU68780/98A priority patent/AU6878098A/en
Priority to IL13149298A priority patent/IL131492A0/xx
Priority to JP54699898A priority patent/JP2001524108A/ja
Priority to EP98914420A priority patent/EP0979105A1/fr
Publication of WO1998048839A1 publication Critical patent/WO1998048839A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Definitions

  • Topical nasal antiinflammatory preparations are known in the art for the treatment of inflammatory conditions of the nasal mucous membranes, and in particular for relief of the symptoms of nasal and sinus conditions such as rhinitis.
  • nasal and sinus conditions may be characterized by diverse symptoms requiring treatment with multiple therapeutic agents.
  • allergic rhinitis may be characterized by rhinorrhea, nasal itching, sneezing, congestion and postnasal drip and treatment may require antihistamines, decongestants, antiallergics and anesthetics in addition to antiinflammatories.
  • the use of multiple topical nasal preparations to administer multiple therapeutic agents suffers from significant disadvantages.
  • the volume of liquid that can effectively be applied nasally is limited by the surface area of the nostril and the bioadhesiveness of the liquid.
  • a sufficient contact time between topical preparations and the surface area of the nostril is required to assure adequate dosing of a therapeutic agent.
  • spray formulations require a threshold surface tension to form droplets.
  • the delivery volume per actuation is limited to the volume that will be retained in the nostril without premature drainage.
  • multiple topical nasal preparations cannot be effectively administered simultaneously.
  • Another disadvantage of the administration of multiple topical nasal preparations is patient inconvenience. Patient compliance may be compromised by the inconvenience of applying multiple spray products or nose drops. Patients complain when excess spray drains into their throats where it can be tasted, resulting in a need for flavor masking of bitter medicaments.
  • the present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, an anticholinergic agent, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anesthetic, and a mucolytic agent.
  • the present invention provides topically applicable nasal compositions comprising a topical antiinflammatory agent and at least one additional therapeutic agent.
  • the present compositions are useful for the treatment of nasal and sinus conditions, for example allergic rhinitis or the common cold.
  • the topical antiinflammatory agents in the compositions of the present invention are corticosteroids known in the art to suppress inflammation.
  • the topical antiinflammatory agent is beclomethasone diproprionate, budesonide, dexamethasone, mometasone furoate, fluticasone proprionate or triamcinolone acetonide.
  • the compositions contain a therapeutically effective amount of the selected antiinflammatory agent. Those of ordinary skill in the art can determine an amount that is therapeutically effective for the suppression of inflammation. The precise amount will depend upon the method of administration and the age, weight and condition of the subject to be treated. Generally the antiinflammatory agents are utilized in dosages known in the art to be therapeutically effective upon nasal administration.
  • compositions of the invention further comprise at least one additional therapeutic agent, and thus allow the convenient administration of an antiinflammatory agent and at least one additional therapeutic agent in a single topical nasal composition.
  • the additional therapeutical agent is suitable for topical nasal administration and is selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an anticholinergic agent, an antihistamine, an antiallergic agent, a local anesthetic and a mucolytic agent.
  • the use of an additional therapeutic agent in combination with an antiinflammatory agent provides additive and synergistic effects in the treatment of nasal and sinus conditions.
  • Vasoconstrictors suitable for topical nasal administration in the compositions of the present invention are oxymetazoline naphazoline, xylometazoline, and phenylephrine.
  • Leukotriene inhibitors include zafirlukast, a selective, competitive receptor antagonist of the three leukotrienes C4, D4, and E4; pranlukast, a selective, competitive receptor antagonist of D4; and zileuton, a leukotriene inhibitor.
  • A. neuramidinase inhibitor includes zanamivir (GG-167).
  • Suitable antihistamines are diphenhydramine, chlorpheniramine, cetirizine terfenadine, fenofexadine, astemizole norastemizole, azelastine, and azatidine.
  • Antiallergic agents include cromolyn sodium and nedocromil levocabastine.
  • An anticholinergic agent useful in the compositions of the present invention is ipratropium bromide.
  • Local topical anesthetics include dyclonine, pramoxine, and benzocaine.
  • Mucolytic agents suitable for topical nasal administration are acetylcysteine, guaifenisin and mucocysteine. The therapeutically effect amount of foregoing agents can be determined by the ordinarily skilled artisan with regard to the known use of these agents in the art and taking into account the method of administration and the age, weight and condition of the subject to be treated.
  • compositions of the present invention are formulated as aqueous solutions comprising an antiinflammatory agent and at least one additional therapeutic agent and further comprising a pharmaceutically acceptable nasal carrier.
  • the formulation of pharmaceutical compositions is generally known in the art and reference can be conveniently made to standard text such as Remington's Pharmaceutical Sciences, 1985, 17th ed., Mack Publishing Co., Easton, Pennsylvania.
  • Preferred nasal formulations are nose drops or nasal sprays containing a water buffered aqueous solution as a carrier.
  • the compositions are preferably isotonic. Isotonic agents such as a sugars and sodium chloride are known in the art and may be included in the subject compositions.
  • compositions of the present invention may also contain a humectant to increase viscosity and effect moisturization and ciliary vitality.
  • Suitable humectants include glycerin, polyethylene glycol, propylene glycol and mixtures thereof.
  • compositions including pharmaceutically acceptable preservatives, stabilizers, flavoring agents, and pH adjusters are known in the art and may be included in the present compositions.
  • Another embodiment of the present invention provides preservative- free compositions comprising an anti-inflammatory agent and at least one additional therapeutic agent. Preservative-free compositions are preferred due to reduced sensitivity and increased patient acceptance. These can be prepared in unit dose or in systems which prevent contamination of the reservoir of solution.
  • the compositions of the present invention can be conveniently administered nasally to a human subject in dosage unit form to elicit the desired therapeutic effect of the antiinflammatory agent and the additional therapeutic agents described above.
  • the compositions may be administered in the form of a nasal spray or nose drops.
  • Nasal sprays may be provided as squeeze bottles or metered dose manual nasal spray pumps designed to deliver the desired dose in one or two sprays, for example.
  • the composition may also be administered as aerosol spray formulations, for example as metered dose pressurized aerosols containing propellants such as halogenated hydrocarbons.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions pour application nasale topique, qui renferment une quantité thérapeutiquement efficace d'agent antiinflammatoire et une quantité thérapeutiquement efficace d'au moins un agent choisi parmi le groupe suivant : vasoconstricteur, inhibiteur de neuramidinase, inhibiteur de leucotriène, antihistaminique, antiallergique, anticholinergique, anesthésique et mucolytique. Ces compositions sont utiles sous forme de pulvérisations ou de gouttes nasales, pour le traitement d'affections du nez et des sinus.
PCT/US1998/006483 1997-04-30 1998-04-02 Compositions antiinflammatoires pour application nasale topique WO1998048839A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR9809022-4A BR9809022A (pt) 1997-04-30 1998-04-02 Composições antiinflamatórias nasais tópicas
CA002281789A CA2281789A1 (fr) 1997-04-30 1998-04-02 Compositions antiinflammatoires pour application nasale topique
AU68780/98A AU6878098A (en) 1997-04-30 1998-04-02 Topical nasal antiinflammatory compositions
IL13149298A IL131492A0 (en) 1997-04-30 1998-04-02 Topical nasal antiinflammatory compositions
JP54699898A JP2001524108A (ja) 1997-04-30 1998-04-02 局所経鼻抗炎症組成物
EP98914420A EP0979105A1 (fr) 1997-04-30 1998-04-02 Compositions antiinflammatoires pour application nasale topique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4430697P 1997-04-30 1997-04-30
US60/044,306 1997-04-30

Publications (1)

Publication Number Publication Date
WO1998048839A1 true WO1998048839A1 (fr) 1998-11-05

Family

ID=21931638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006483 WO1998048839A1 (fr) 1997-04-30 1998-04-02 Compositions antiinflammatoires pour application nasale topique

Country Status (8)

Country Link
EP (1) EP0979105A1 (fr)
JP (1) JP2001524108A (fr)
CN (1) CN1253508A (fr)
AU (1) AU6878098A (fr)
BR (1) BR9809022A (fr)
CA (1) CA2281789A1 (fr)
IL (1) IL131492A0 (fr)
WO (1) WO1998048839A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032125A1 (fr) * 1997-12-23 1999-07-01 Schering Corporation Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
US6039974A (en) * 1997-08-26 2000-03-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
WO2000021510A2 (fr) * 1998-10-13 2000-04-20 West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. Nouvelles formulations de fexofenadine
WO2001007019A2 (fr) * 1999-07-27 2001-02-01 Zambon Group S.P.A. Utilisation de n-acetyle cysteine pour la preparation de compositions pharmaceutiques topiques destinees au traitement de pathologies allergiques des voies respiratoires
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
WO2003024433A2 (fr) * 2001-09-18 2003-03-27 Nycomed Danmark Aps Compositions pour traiter le rhume
GB2389530A (en) * 2002-06-14 2003-12-17 Cipla Ltd Pharmaceutical composition comprising azelastine and steroid
WO2005013963A1 (fr) * 2003-08-06 2005-02-17 Galephar M/F Combinaisons avantageuses pour inhalation de nacystelyn et de bronchodilatateurs
JP2008013580A (ja) * 1999-07-06 2008-01-24 Naryx Pharma Inc 副鼻腔炎を処置するためのエアロゾル化された抗感染剤、抗炎症剤および鬱血除去剤
US7879832B2 (en) 2002-08-30 2011-02-01 Nycomed Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US8093301B2 (en) * 2005-08-26 2012-01-10 Meiji Co., Ltd. Anti-allergic agent
US8637469B2 (en) 2006-07-11 2014-01-28 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
US9980959B2 (en) 2004-05-11 2018-05-29 Biolipox Ab Method and composition for treating rhinitis
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373033A1 (en) * 2002-06-20 2005-08-08 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
JP2008143845A (ja) * 2006-12-11 2008-06-26 Hoshienu Seiyaku Kk 点鼻薬組成物及び点鼻薬液噴霧器具
BR112014029442A2 (pt) * 2012-05-25 2017-06-27 Xlear Inc composições antimucosas à base de xilitol e métodos e composições relacionados
CN104667256B (zh) * 2015-03-18 2017-05-03 江苏威克斯医疗科技有限公司 一种鼻腔粘膜纤毛护理冲洗液及其用途
CN107753485A (zh) * 2017-11-28 2018-03-06 赵永宏 一种兼有鼻减充血和麻醉作用的药物组合物及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482015A (en) * 1965-02-08 1969-12-02 Merck & Co Inc Aerosol composition of phenylephrine tartrate and the production of such
US4053628A (en) * 1971-05-12 1977-10-11 Fisons Limited Composition
WO1985004589A1 (fr) * 1984-04-09 1985-10-24 Abraham Sunshine Melanges contre la toux et le rhume comprenant des medicaments anti-inflammatoires non steraniques
JPS62153227A (ja) * 1985-12-26 1987-07-08 Sekisui Chem Co Ltd 経皮・経粘膜製剤
WO1993009764A1 (fr) * 1991-11-19 1993-05-27 Center For Innovative Technology Traitement des rhumes a l'aide d'une therapie associant des agents antimediatiques et virostatiques (covam)
WO1995007103A1 (fr) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions contenant un sel d'acide amine d'un agent anti-inflammatoire non steroidien a base d'acide propionique et au moins un decongestionnant ou un expectorant ou un antihistaminique ou un antitussif
WO1997001341A1 (fr) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'agents de stabilisation de mastocytes nasaux topiques avec des steroides nasaux topiques
WO1997001337A1 (fr) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'antihistamines et de steroides a application topique par voie nasale
WO1997009067A1 (fr) * 1995-09-05 1997-03-13 Bayer Aktiengesellschaft Association d'inhibiteurs de la lipoxygenase-5 et de la synthese de leucotrienes avec des glucocorticosteroides
EP0780127A1 (fr) * 1995-12-19 1997-06-25 The Procter & Gamble Company Pulvérisateur nasale contenant un stéréoide et un antihistamine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482015A (en) * 1965-02-08 1969-12-02 Merck & Co Inc Aerosol composition of phenylephrine tartrate and the production of such
US4053628A (en) * 1971-05-12 1977-10-11 Fisons Limited Composition
WO1985004589A1 (fr) * 1984-04-09 1985-10-24 Abraham Sunshine Melanges contre la toux et le rhume comprenant des medicaments anti-inflammatoires non steraniques
JPS62153227A (ja) * 1985-12-26 1987-07-08 Sekisui Chem Co Ltd 経皮・経粘膜製剤
WO1993009764A1 (fr) * 1991-11-19 1993-05-27 Center For Innovative Technology Traitement des rhumes a l'aide d'une therapie associant des agents antimediatiques et virostatiques (covam)
WO1995007103A1 (fr) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions contenant un sel d'acide amine d'un agent anti-inflammatoire non steroidien a base d'acide propionique et au moins un decongestionnant ou un expectorant ou un antihistaminique ou un antitussif
WO1997001341A1 (fr) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'agents de stabilisation de mastocytes nasaux topiques avec des steroides nasaux topiques
WO1997001337A1 (fr) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. Combinaison d'antihistamines et de steroides a application topique par voie nasale
WO1997009067A1 (fr) * 1995-09-05 1997-03-13 Bayer Aktiengesellschaft Association d'inhibiteurs de la lipoxygenase-5 et de la synthese de leucotrienes avec des glucocorticosteroides
EP0780127A1 (fr) * 1995-12-19 1997-06-25 The Procter & Gamble Company Pulvérisateur nasale contenant un stéréoide et un antihistamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8733, Derwent World Patents Index; AN 87-230755, XP002067758 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039974A (en) * 1997-08-26 2000-03-21 Hoechst Marion Roussel, Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
KR100737710B1 (ko) * 1997-12-23 2007-07-11 쉐링 코포레이션 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물
WO1999032125A1 (fr) * 1997-12-23 1999-07-01 Schering Corporation Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
AU758771B2 (en) * 1997-12-23 2003-03-27 Merck Sharp & Dohme Corp. Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
WO2000021510A2 (fr) * 1998-10-13 2000-04-20 West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. Nouvelles formulations de fexofenadine
WO2000021510A3 (fr) * 1998-10-13 2000-07-20 West Pharm Serv Drug Res Ltd Nouvelles formulations de fexofenadine
JP2008013580A (ja) * 1999-07-06 2008-01-24 Naryx Pharma Inc 副鼻腔炎を処置するためのエアロゾル化された抗感染剤、抗炎症剤および鬱血除去剤
WO2001007019A2 (fr) * 1999-07-27 2001-02-01 Zambon Group S.P.A. Utilisation de n-acetyle cysteine pour la preparation de compositions pharmaceutiques topiques destinees au traitement de pathologies allergiques des voies respiratoires
WO2001007019A3 (fr) * 1999-07-27 2001-09-27 Zambon Spa Utilisation de n-acetyle cysteine pour la preparation de compositions pharmaceutiques topiques destinees au traitement de pathologies allergiques des voies respiratoires
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6436924B2 (en) 2000-02-17 2002-08-20 Asta Medica Ag Antihistamine leukotriene combinations
US7652030B2 (en) 2001-09-18 2010-01-26 Nycomed Danmark Aps Compositions for treatment of common cold
WO2003024433A2 (fr) * 2001-09-18 2003-03-27 Nycomed Danmark Aps Compositions pour traiter le rhume
EP1661570A2 (fr) * 2001-09-18 2006-05-31 Nycomed Danmark ApS Compositions comprenant de l'ipatropium et de la xylometazoline pour le traitement du rhume
US8450339B2 (en) 2001-09-18 2013-05-28 Takeda Pharma A/S Compositions for treatment of common cold
EA008165B1 (ru) * 2001-09-18 2007-04-27 Никомед Данмарк Апс Композиции для лечения простуды
WO2003024433A3 (fr) * 2001-09-18 2004-06-10 Nycomed Danmark Aps Compositions pour traiter le rhume
EP1661570A3 (fr) * 2001-09-18 2012-10-24 Nycomed Danmark ApS Compositions comprenant de l'ipatropium et de la xylometazoline pour le traitement du rhume
US8304405B2 (en) 2002-06-14 2012-11-06 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
US8933060B2 (en) 2002-06-14 2015-01-13 Cipla Limited Combination of azelastine and ciclesonide for nasal administration
US9901585B2 (en) 2002-06-14 2018-02-27 Cipla Limited Combination of azelastine and fluticasone for nasal administration
US9259428B2 (en) 2002-06-14 2016-02-16 Cipla Limited Combination of azelastine and fluticasone for nasal administration
US8163723B2 (en) 2002-06-14 2012-04-24 Cipla Limited Combination of azelastine and steroids
GB2389530A (en) * 2002-06-14 2003-12-17 Cipla Ltd Pharmaceutical composition comprising azelastine and steroid
US8937057B2 (en) 2002-06-14 2015-01-20 Cipla Limited Combination of azelastine and mometasone for nasal administration
US8318709B2 (en) 2002-06-14 2012-11-27 Cipla Limited Combination of azelastine and mometasone for nasal administration
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8486923B2 (en) 2002-08-30 2013-07-16 Takeda Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US7879832B2 (en) 2002-08-30 2011-02-01 Nycomed Gmbh Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
EP2295062A1 (fr) 2002-08-30 2011-03-16 Nycomed GmbH Utilisation de la combinaison de ciclesonide et des antihistamines pour le traitement de rhinite allergique
WO2005013963A1 (fr) * 2003-08-06 2005-02-17 Galephar M/F Combinaisons avantageuses pour inhalation de nacystelyn et de bronchodilatateurs
US9980959B2 (en) 2004-05-11 2018-05-29 Biolipox Ab Method and composition for treating rhinitis
US9919050B2 (en) 2004-11-24 2018-03-20 Meda Pharmaceuticals Inc. Compositions comprising azelastine
US10064817B2 (en) 2004-11-24 2018-09-04 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8093301B2 (en) * 2005-08-26 2012-01-10 Meiji Co., Ltd. Anti-allergic agent
US8637469B2 (en) 2006-07-11 2014-01-28 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP2851064A3 (fr) * 2006-07-11 2015-08-05 Roy C. Levitt Prévention de la rhinosinusite et thérapie avec des inhibiteurs de cytokine proinflammatoires

Also Published As

Publication number Publication date
IL131492A0 (en) 2001-01-28
EP0979105A1 (fr) 2000-02-16
JP2001524108A (ja) 2001-11-27
BR9809022A (pt) 2000-08-01
CN1253508A (zh) 2000-05-17
AU6878098A (en) 1998-11-24
CA2281789A1 (fr) 1998-11-05

Similar Documents

Publication Publication Date Title
EP0979105A1 (fr) Compositions antiinflammatoires pour application nasale topique
EP1227812B1 (fr) Traitement nasal topique avec la desloratadine et furoate du mometasone
ES2617255T3 (es) Composiciones que comprenden azelastina y métodos de uso de las mismas
AU651089B2 (en) Treatment of sinus headache
JP4500045B2 (ja) 感冒の治療のための組成物
US20050281751A1 (en) Directed intranasal administration of pharmaceutical agents
US20030049322A1 (en) Aqueous-based pharmaceutical composition
EP0780127A1 (fr) Pulvérisateur nasale contenant un stéréoide et un antihistamine
US20020193417A1 (en) Nasal solutions
JPH11511758A (ja) 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬
AU2012216890A1 (en) Combination of glycopyrrolate and a beta2 -agonist
SK283338B6 (sk) Použitie mometazónfuroátu na prípravu liečiva na liečenie chorôb horných a dolných dýchacích ciest a pľúc
WO2004023984A2 (fr) Composition et procede pour le traitement des affections des voies respiratoires superieures
WO1999038492A1 (fr) Preparations pharmaceutiques
RU2472499C2 (ru) Лекарственное средство, включающее комбинацию активных веществ, содержащую пантотеновую кислоту или ее производные, для лечения аллергических симптомов
JP2011520894A (ja) 鼻性鼻炎の治療に使用するための組換えヒトｃｃ１０およびその組成物
ES2740103T3 (es) Uso de una composición que comprende formoterol y dipropionato de beclometasona para la prevención y/o el tratamiento de una exacerbación de asma
RU2005135332A (ru) Назальные фармацевтические композиции и способы их применения
ES2340777T3 (es) Metodo de tratamiento de la rinosinusitis aguda.
US4385048A (en) Methods for the treatment of nasal hypersecretion
JPS6034909A (ja) いびき止め剤
McAllen et al. Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis
US7332528B2 (en) DRI nasal sprays
MXPA99007597A (en) Topical nasal antiinflammatory compositions
US20020151562A1 (en) Compositions and methods for treating allergic fungal sinusitis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131492

Country of ref document: IL

Ref document number: 98804579.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE GW HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2281789

Country of ref document: CA

Ref document number: 2281789

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 68780/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/007597

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 337347

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1998 546998

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998914420

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09423105

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998914420

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998914420

Country of ref document: EP